MedTrace Logo

Immunogenicity Induced by COVID-19 Vaccines in Mexican Population

NCT06597370 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2024-10-04

No results posted yet for this study

Summary

To determine the gene expression of anti-spike IgG through PCR-RT in patients vaccinated with the 4 types of vaccines available in Mexico Oxford/AstraZeneca (ChAdOx1 nCoV-19), Centro Nacional Gamaleya (Sputnik V), Pfizer/BioNTech (BNT162b2) and Sinovac (CoronaVac).

Conditions

  • COVID-19 Vaccine

Interventions

OTHER

Gene expression mRNA of IgG anti-spike

b) Peripheral venous blood samples (3 ml per occasion) will be taken from all participants. They will be carried out on days 30,60 and 120 after completion of the COVID-19 vaccination schedule. c) Sample processing: * tRNA extraction from all samples. * cDNA synthesis * Real time PCR performance.

Sponsors & Collaborators

  • National Polytechnic Institute, Mexico

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2021-12-20
Completion
2021-12-21

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06597370 on ClinicalTrials.gov